- Docket Number:
- Issued by:
Guidance Issuing OfficeCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research
This guidance describes best practices pertaining to conducting and reporting on pharmacoepidemiologic safety studies2 that use electronic healthcare data, which include administrative claims data and electronic medical record (EMR) data.3 The guidance includes recommendations for documenting the design, analysis, and results of pharmacoepidemiologic safety studies to optimize FDA’s review of protocols and final reports that are submitted to the Agency. For purposes of this guidance, the term pharmacoepidemiologic safety study refers to an observational study designed to assess the risk associated with a drug exposure and to test prespecified hypotheses. For ease of reference, this guidance uses the term drug to refer to drug and biological products regulated by CDER or CBER. Medical devices are not within the scope of this guidance.
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2011-D-0057.